



September 25, 2025

**The General Manager,
Corporate Services/Listing Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 539730

Sub: Outcome of Board Meeting held on 25th September, 2025 under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir,

With reference to above, we hereby inform you that the Board of Directors of Fredun Pharmaceuticals Limited (**the "Company"**) at their meeting held today has approved the following:

1. The issuance of upto **6,52,360 (Six Lakhs Fifty Two Thousand Three Hundred and Sixty)** fully paid-up equity shares of the Company of face value of Re. 10/- (Rupees Ten only) each at an issue price of Rs. 1250/- (Rupees Twelve Hundred and Fifty only) per equity share [including a securities premium of Rs.1240/- (Rupees Twelve Hundred and Forty only)] to the proposed allottees, as detailed in Annexure A1 and A2, belonging to the Promoters and Non-Promoter category ("Investors"), by way of a preferential issue on a private placement basis ("Preferential Issue"), in accordance with the provisions of Section 42 and Section 62 of the Companies Act, 2013, as amended ("Act") read with the Companies (Prospectus and Allotment of Securities) Rules, 2014, as amended ("Rules"), Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), SEBI Listing Regulations and other acts / rules / regulations as maybe applicable and subject to necessary eligibility, approval of the shareholders of the Company and other regulatory authorities including BSE Limited, as may be applicable.
2. The issuance of up to **5,73,600 (Five Lakhs Seventy Three Thousand and Six Hundred)** convertible warrants, with each warrant being convertible into one equity share of the company with a face value of ₹10 (Rupees Ten only) at an issue price of ₹1,250/- (Rupees One Thousand Two Hundred and Fifty only), which includes a securities premium of ₹1,240 (Rupees One Thousand Two Hundred and Forty only). This preferential issue, conducted on a private placement basis, is to be made to proposed allottees, from both promoter and non-promoter categories, as detailed in Annexure A1 and A2, in compliance with the provisions of Sections 42 and 62 of the Companies Act, 2013, the Companies (Prospectus and Allotment of Securities) Rules, 2014, Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI Listing Regulations, and other applicable rules, subject to receiving the necessary eligibility, shareholder approval, and other regulatory approvals, including from BSE Limited.



The disclosures as required under Regulation 30 of SEBI Listing Regulations read with SEBI's Master Circular dated November 11, 2024, are given in **Annexure A1 and A2**.

3. The Board, in the aforesaid connection, approved the issue of Notice for convening Extra-Ordinary General Meeting ("**EGM**") of the shareholders of the Company to be held on Wednesday, 22nd October, 2025 through video conferencing or other audio-visual means, to seek necessary approval of the shareholders for the proposed Preferential Issue.

The meeting commenced at 03:00 p.m. and concluded at 08:30 p.m.

This is for your information and records.

Thanking You.

Yours truly,

FOR FREDUN PHARMACEUTICALS LIMITED

**FREDUN MEDHORA
MANAGING DIRECTOR
DIN: 01745348**



Annexure A1

Disclosure of Event and Information pursuant to as required under Regulation 30 of SEBI Listing Regulations read with SEBI's Master Circular dated November 11, 2024.

1. Issuance of Securities

Sr. No.	Particulars of Securities	Details of Securities	
a)	Type of securities proposed to be issued	Equity Shares	Warrants
b)	Type of issuance	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.	
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued	6,52,360 (Six Lakhs Fifty Two Thousand Three Hundred and Sixty) fully paid-up equity shares Equity Shares.	5,73,600 (Five Lakhs Seventy Three Thousand and Six Hundred) Convertible Warrants.
In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s):			
i.	Name of Investors	Enclosed as Annexure A2	
ii.	Post Allotment of securities - outcome of the subscription	Not Applicable	Not Applicable
iii.	Issue price	Equity Share of face value of Rs.10/- (Rupees Ten only) each at Issue Price of Rs.1250/- (Rupees Twelve Hundred and Fifty only) per Equity Share.	Share Warrants of Rs.10/- (Rupees Ten only) each at Issue Price of Rs.1250/- (Rupees Twelve Hundred and Fifty only) per Share Warrant.
iv.	Number of investors		
iii.	in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not Applicable	25% of the Consideration of the Warrant would be payable at the time of application and the balance would be payable at the time of conversion of the Warrants into Equity Shares. Each Warrant is convertible into 1 Equity Shares and the



			conversion can be exercised at any time within a period of 18 months from the date of allotment, in one or more tranches, as the case may be and on such other terms and conditions as applicable.
--	--	--	--

**Annexure A2**

Sr.no.	Name of Investors	Category of Investor
1.	Fredun Nariman Medhora	Promoter
2.	Daulat Medhora	Promoter
3.	Alchemy Capital Management Pvt Ltd	Non-Promoter
4.	Alchemy Long Term Ventures Fund, Series 2	Non-Promoter
5.	Nav Capital VCC-Nav Capital Emerging Star Fund	Non-Promoter
6.	Navbharat Investment Trust- Navbharat Investment Opportunities Fund	Non-Promoter
7.	Capri Global Holdings Private Limited	Non-Promoter
8.	R R Family Trust	Non-Promoter
9.	Divya Arora	Non-Promoter
10.	Ajay Kumar Aggarwal	Non-Promoter
11.	Neha Lashit Sanghvi	Non-Promoter
12.	Karthik Sundar	Non-Promoter
13.	Shruthi M	Non-Promoter
14.	Vanaja Sundar Iyer	Non-Promoter
15.	Nikhil Ramesh Jaisinghani	Non-Promoter
16.	Girdhari Thakurdas Jaisinghani	Non-Promoter
17.	Reshma Manish Kukreja	Non-Promoter
18.	Juhi Hemant Ramnani	Non-Promoter
19.	Karina C Moriani	Non-Promoter
20.	Divya Aggarwal	Non-Promoter
21.	Niharika Agarwal	Non-Promoter
22.	Swati Goel	Non-Promoter
23.	Sahil Dhir	Non-Promoter
24.	Rinkle Jain	Non-Promoter
25.	Rashmi Jain	Non-Promoter
26.	Ujjyara Sarees Private Limited	Non-Promoter
27.	Priyabhakta Commotrade Private Limited	Non-Promoter
28.	Mohak Rajesh Gupta	Non-Promoter
29.	Pulak Patodia	Non-Promoter
30.	Vrinda Patodia	Non-Promoter
31.	Sweta Chokhany	Non-Promoter
32.	Vartika Chokhany	Non-Promoter
33.	Somani Stock Broking Pvt Ltd	Non-Promoter
34.	Aryavrat Financial Services Private Limited	Non-Promoter



35.	Vivek Dhir	Non-Promoter
36.	Sona Vets Private Limited	Non-Promoter
37.	H&A Ventures (On behalf of Shipra Bhutra)	Non-Promoter
38.	Dhiren Mahendrakumar Shah	Non-Promoter
39.	Harish Sitaram Sharma	Non-Promoter
40.	Sanjay Sinha	Non-Promoter
41.	Sachin Gupta	Non-Promoter
42.	Patel Janki Siddharth	Non-Promoter
43.	Kedar Ramesh Deshpande	Non-Promoter
44.	Prithvisramachandra Vashist	Non-Promoter
45.	Dhananjay Advisors (On behalf of Reetu Rani)	Non-Promoter
46.	Instanow Info Systems Private Limited	Non-Promoter
47.	Rajesh Suryakant Gandhi (HUF)	Non-Promoter
48.	Archana Kapur	Non-Promoter
49.	Tanvi Achariya	Non-Promoter
50.	Jinendra G	Non-Promoter
51.	Gothamchand A	Non-Promoter
52.	Shagun Capital Venture (on behalf of Shankesh Vijayakumar and Manav Vijayakumar)	Non-Promoter
53.	Ceramet Consultants Pvt Ltd	Non-Promoter
54.	Nav Ratan Bhaiya	Non-Promoter
55.	Prithish Garg	Non-Promoter
56.	Indu Ramanlal Golecha	Non-Promoter
57.	Pinky Akashkumar	Non-Promoter
58.	Amit Gunchandra Mehta	Non-Promoter
59.	Himanshu Sureshchandra Shah	Non-Promoter
60.	Nimisha Amit Kothari	Non-Promoter
61.	Dhiren Chandulal Shah	Non-Promoter
62.	Czar Capital Private Limited	Non-Promoter
63.	Hiten B Shah (HUF)	Non-Promoter
64.	Jeel Hiten Shah	Non-Promoter
65.	Gajjar Anuradha Himansu	Non-Promoter